Medtrum moves 300U patch pump toward Germany launch

Medtrum said July 27, 2026, that its higher-capacity 300U tubeless patch pump is advancing toward launch in Germany after a DDG 2026 presentation in Berlin and listing in the country’s statutory health insurance medical aids directory. The move expands the TouchCare Nano System and signals a broader push across Europe.

Why it matters: - The 300U pump gives people who need larger insulin doses a 50% higher reservoir capacity than common 200-unit patch pumps. - The larger reservoir can reduce how often users need to replace the pump and may make daily insulin therapy easier to manage. - The listing in Germany’s statutory health insurance medical aids directory and the new reimbursement code are important steps toward commercial launch in one of Europe’s most important diabetes technology markets.

What happened: - Medtrum announced further progress toward the German launch of its 300-unit tubeless patch pump on July 27, 2026. - The company highlighted the pump’s presentation at DDG 2026 in Berlin. - The 300U version was listed in Germany’s statutory health insurance medical aids directory, known as GKV-Hilfsmittelverzeichnis. - The pump received its own reimbursement code in Germany.

The details: - The 300U pump keeps the same discreet, tubeless, body-worn design as Medtrum’s 200-unit patch pumps. - The 300U pump is already available in selected international markets. - Medtrum said the new option expands its tubeless insulin delivery portfolio in Europe. - At DDG 2026, the 300U pump was central to Medtrum’s exhibition theme, “Medtrum macht mehr möglich” (“Medtrum makes more possible”). - The 300U pump is part of the TouchCare Nano System. - The TouchCare Nano System combines tubeless patch pump therapy, continuous glucose monitoring, the APGO® automated insulin delivery algorithm, mobile app control and remote data sharing. - Medtrum said the system helps users monitor glucose trends, automate insulin delivery, simplify mealtime insulin decisions and keep caregivers informed when needed. - Medtrum technologies are available in more than 50 countries and regions. - In 2024, the TouchCare AID System received CE certification under the EU Medical Device Regulation as a Class III medical device. - Medtrum’s official website provides more information about the company and the TouchCare Nano System: More information.

Between the lines: - The Germany milestones suggest Medtrum is pairing product expansion with the regulatory and reimbursement work needed to move from market access to sales. - Medtrum is using European diabetes conferences to show both clinical research and new product features, which can help support adoption with clinicians and payers. - CEO Scott Yang said Germany is a strategic market for Medtrum’s broader European expansion and that the company plans to strengthen direct commercial operations, partnerships and clinical evidence generation. - At ATTD 2026, Medtrum also presented enhancements to SmartRun™ Advanced Auto Mode and Auto Meal Handling. - Auto Meal Handling lets users announce a meal type instead of doing a full carbohydrate calculation, which Medtrum says simplifies interaction with the AID system.

What’s next: - Medtrum will keep engaging healthcare professionals, clinical partners and industry stakeholders through scientific congresses, clinical collaborations and evidence-generation efforts. - The company said upcoming activity includes the 62nd EASD Annual Meeting this fall in Milan. - Medtrum plans to continue the dialogue around connected diabetes care and changing needs among people with diabetes.

The bottom line: - Medtrum is turning a product update into a broader European growth push, with Germany positioned as a key test of its higher-capacity patch pump strategy.